Amedisys (AMED) Tops Q4 EPS by 18c; Issues FY23 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Join SI Premium – FREE
Amedisys (NASDAQ: AMED) reported Q4 EPS of $1.16, $0.18 better than the analyst estimate of $0.98. Revenue for the quarter came in at $562 million versus the consensus estimate of $560.59 million.
GUIDANCE:
Amedisys sees FY2023 EPS of $4.13-$4.36, versus the consensus of $4.86. Amedisys sees FY2023 revenue of $2.244-2.274 billion, versus the consensus of $2.36 billion.
For earnings history and earnings-related data on Amedisys (AMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Wells Fargo Names Top Pick Ahead of Q3 Earnings
- Top restaurant stocks to watch, according to Raymond James
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
